Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?
1. MBRX stock surged 426% to $2.21 on Thursday. 2. FDA feedback allows 10% reduction in trial size for Annamycin. 3. Phase 3 trial timeliness supports accelerated drug approval strategy. 4. First unblinding expected in 2025 with significant data insights. 5. Annamycin holds Fast Track and Orphan Drug Designation.